23:31 , Oct 11, 2018 |  BC Week In Review  |  Company News

Philadelphia groups partner to target Tregs for lung cancer

AUM LifeTech Inc. (Philadelphia, Pa.), Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania partnered to develop an RNA silencing immunotherapy to treat lung cancer. The therapeutic, which...
22:19 , Oct 11, 2018 |  BC Innovations  |  Translation in Brief

Public funding highlights: 3Q18

Public funding highlights: 3Q18...
00:12 , Oct 10, 2018 |  BC Extra  |  Preclinical News

In utero base editing corrects metabolic birth defect

Researchers from Children's Hospital of Philadelphia and University of Pennsylvania opened the door to prenatal genome editing by using a relatively new CRISPR-based approach called base editor 3 to correct tyrosinemia type I, a rare...
20:34 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Adcetris meets in Phase III for first-line PTCL

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Adcetris brentuximab vedotin plus chemotherapy met the primary and all key secondary endpoints in the Phase III ECHELON-2 trial to treat previously untreated CD30-expressing...
19:19 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

New risdiplam data show improvements in developmental milestones

PTC Therapeutics Inc. (NASDAQ:PTCT) and Genentech Inc. reported updated data from part I of the two-part Phase II/III FIREFISH and SUNFISH trials of risdiplam (RG7916) to treat spinal muscular atrophy (SMA) that highlighted improvements in...
23:26 , Oct 3, 2018 |  BC Extra  |  Clinical News

New risdiplam data show improvements in developmental milestones

PTC Therapeutics Inc. (NASDAQ:PTCT) and Genentech Inc. reported updated data from part I of the two-part Phase II/III FIREFISH and SUNFISH trials of risdiplam (RG7916) to treat spinal muscular atrophy (SMA) that highlighted improvements in...
02:01 , Sep 29, 2018 |  BioCentury  |  Politics, Policy & Law

PROs in prime time

A recommendation by CMS’s MEDCAC catapults the collection of PRO data to the postmarket setting from their more familiar spot in clinical development. CAR T leaders Novartis AG and Gilead Sciences Inc., however, are not...
15:17 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Otologic

INDICATION: Hearing loss Mouse studies suggest inhibiting DDIT3 or PERK could help treat hearing loss. In a mouse model of genetic hearing loss, systemic knockout of DDIT3 decreased hearing loss compared with normal DDIT3 expression....
18:26 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Audentes reports Phase I/II muscle biopsy data for myopathy gene therapy

Audentes Therapeutics Inc. (NASDAQ:BOLD) reported data from its 24-week muscle biopsy analyses of the first dose cohort and said an IDMC recommended proceeding to the second dose cohort of the Phase I/II ASPIRO trial evaluating...
17:43 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Imbruvica plus chemotherapy misses in Phase III for subtype of DLBCL

AbbVie Inc. (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) said Imbruvica ibrutinib plus R-CHOP chemotherapy missed the primary endpoint of improving event-free survival vs. placebo plus R-CHOP chemotherapy in the Phase III PHOENIX trial to treat...